169 related articles for article (PubMed ID: 21295584)
21. Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells.
Sinha S; Grandgenett DP
J Virol; 2005 Jul; 79(13):8208-16. PubMed ID: 15956566
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 Group O Resistance Against Integrase Inhibitors.
Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.
Bar-Magen T; Sloan RD; Donahue DA; Kuhl BD; Zabeida A; Xu H; Oliveira M; Hazuda DJ; Wainberg MA
J Virol; 2010 Sep; 84(18):9210-6. PubMed ID: 20610719
[TBL] [Abstract][Full Text] [Related]
24. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase.
Depatureaux A; Quashie PK; Mesplède T; Han Y; Koubi H; Plantier JC; Oliveira M; Moisi D; Brenner B; Wainberg MA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7141-50. PubMed ID: 25224008
[TBL] [Abstract][Full Text] [Related]
26. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
27. Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.
Varadarajan J; McWilliams MJ; Hughes SH
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14747-52. PubMed ID: 23959861
[TBL] [Abstract][Full Text] [Related]
28. Activity of recombinant HIV-1 integrase on mini-HIV DNA.
Cherepanov P; Surratt D; Toelen J; Pluymers W; Griffith J; De Clercq E; Debyser Z
Nucleic Acids Res; 1999 May; 27(10):2202-10. PubMed ID: 10219094
[TBL] [Abstract][Full Text] [Related]
29. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
Hu Z; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Oct; 55(2):148-55. PubMed ID: 20634701
[TBL] [Abstract][Full Text] [Related]
30. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.
Pollicita M; Surdo M; Di Santo F; Cortese MF; Fabeni L; Fedele V; Malet I; Marcelin AG; Calvez V; Ceccherini-Silberstein F; Perno CF; Svicher V
J Antimicrob Chemother; 2014 Sep; 69(9):2412-9. PubMed ID: 24860155
[TBL] [Abstract][Full Text] [Related]
31. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
[TBL] [Abstract][Full Text] [Related]
32. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Nguyen HL; Ruxrungtham K; Delaugerre C
Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
[TBL] [Abstract][Full Text] [Related]
33. Two-long terminal repeat (LTR) DNA circles are a substrate for HIV-1 integrase.
Richetta C; Thierry S; Thierry E; Lesbats P; Lapaillerie D; Munir S; Subra F; Leh H; Deprez E; Parissi V; Delelis O
J Biol Chem; 2019 May; 294(20):8286-8295. PubMed ID: 30971426
[TBL] [Abstract][Full Text] [Related]
34. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
Svarovskaia ES; Barr R; Zhang X; Pais GC; Marchand C; Pommier Y; Burke TR; Pathak VK
J Virol; 2004 Apr; 78(7):3210-22. PubMed ID: 15016842
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors.
Patel M; Naidu BN; Dicker I; Higley H; Lin Z; Terry B; Protack T; Krystal M; Jenkins S; Parker D; Panja C; Rampulla R; Mathur A; Meanwell NA; Walker MA
Bioorg Med Chem; 2020 Jul; 28(13):115541. PubMed ID: 32389483
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 integrase crosslinked oligomers are active in vitro.
Faure A; Calmels C; Desjobert C; Castroviejo M; Caumont-Sarcos A; Tarrago-Litvak L; Litvak S; Parissi V
Nucleic Acids Res; 2005; 33(3):977-86. PubMed ID: 15718297
[TBL] [Abstract][Full Text] [Related]
37. Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.
Dicker IB; Terry B; Lin Z; Li Z; Bollini S; Samanta HK; Gali V; Walker MA; Krystal MR
J Biol Chem; 2008 Aug; 283(35):23599-609. PubMed ID: 18577511
[TBL] [Abstract][Full Text] [Related]
38. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
39. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.
Bercoff DP; Triqueneaux P; Lambert C; Oumar AA; Ternes AM; Dao S; Goubau P; Schmit JC; Ruelle J
Retrovirology; 2010 Nov; 7():98. PubMed ID: 21114823
[TBL] [Abstract][Full Text] [Related]
40. Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.
Beare KD; Coster MJ; Rutledge PJ
Curr Med Chem; 2012; 19(8):1177-92. PubMed ID: 22214459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
